Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform
Published . Updated .
Fintel reports that on September 23, 2026, Oppenheimer initiated coverage of Pacira BioSciences (NASDAQGS:PCRX) (DB:82P) with a Outperform recommendation.Pacira BioSciences, Inc., based in the United States, operates within the pharmaceutical industry and is primarily focused on
Directly affected
- PCRX Pacira BioSciences
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Fintel reports that on September 23, 2026, Oppenheimer initiated coverage of Pacira BioSciences (NASDAQGS:PCRX) (DB:82P) with a Outperform recommendation.Pacira BioSciences, Inc., based in the United States, operates within the pharmaceuti…
Source: Nasdaq Markets
Pacira BioSciences (PCRX) since this story, compared with the market
Since the first closing price after “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform,” Pacira BioSciences (PCRX) is +44.92%. The S&P 500 fund (SPY) is -0.62% over the same days, a +45.53% difference versus the market.
Disclosure records for Pacira BioSciences (PCRX) within two months of 24 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 5 days after publication, inside 30 days. The filing is listed beside the story “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 13 days before publication, inside 30 days. The filing is listed beside the story “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 52 days before publication, inside 60 days. The filing is listed beside the story “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 56 days before publication, inside 60 days. The filing is listed beside the story “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 56 days before publication, inside 60 days. The filing is listed beside the story “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Pacira BioSciences (PCRX)
Companies mentioned with this story
- PCRX Pacira BioSciences
In “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform,” Pacira BioSciences (PCRX) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names PACIRA BIOSCIENCES INC in the headline; GA resolved that company to PCRX
- ACHC Acadia Healthcare
Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform.” Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
For “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
Davita (DVA) is linked, with no stored direction, medium confidence in the 24 Sep 2026 story “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform.” Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
In “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Pacira BioSciences (PCRX)
Pacira BioSciences (PCRX) is the company in “Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform,” the 24 Sep 2026 this story story.
What ties Pacira BioSciences (PCRX) to the headline is this: The reported development directly names PACIRA BIOSCIENCES INC in the headline; GA resolved that company to PCRX
Acadia Healthcare (ACHC) is here too. Its reason reads: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Pacira BioSciences (PCRX)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. PCRX traded between 24.51 and 36.67 across 19 sessions. The latest close on file is 36.36.
How strong the case is around Pacira BioSciences (PCRX)
46 out of 100
“Oppenheimer Initiates Coverage of Pacira BioSciences with Outperform” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.